TF and essential thrombocythemia: It should be stressed that activated platelets and leukocytes in ET patients were found to be the main source of tissue factor (TF) and that reduced activity of the TF pathway inhibitor additionally increases the prothrombotic risk in JAK2V617F positive ET patients (Gadomska et al. 2016).